Trials / Conditions / Primary Central Nervous System Non-Hodgkin Lymphoma

Primary Central Nervous System Non-Hodgkin Lymphoma

13 registered clinical trials studyying Primary Central Nervous System Non-Hodgkin Lymphoma.

Status	Trial	Sponsor	Phase
Terminated	Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Primary Central Nervous System Non-Hodgkin Lymphoma NCT01973062	Case Comprehensive Cancer Center	Phase 2
Completed	Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hemato NCT01789255	National Cancer Institute (NCI)	Phase 2
Completed	Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing NCT01588015	City of Hope Medical Center	Phase 1
Completed	MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia NCT01231919	National Cancer Institute (NCI)	Phase 1
Completed	RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors NCT01158274	National Cancer Institute (NCI)	Phase 1
Completed	Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hod NCT00918333	Mayo Clinic	Phase 1 / Phase 2
Completed	Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction NCT00499811	National Cancer Institute (NCI)	Phase 1
Completed	3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma NCT00293345	National Cancer Institute (NCI)	Phase 1
Completed	PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas NCT00348985	National Cancer Institute (NCI)	Phase 1
Completed	MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas NCT00098891	National Cancer Institute (NCI)	Phase 1
Completed	Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction NCT00025415	National Cancer Institute (NCI)	Phase 1
Completed	17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymph NCT00004241	National Cancer Institute (NCI)	Phase 1
Completed	Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma NCT00003970	National Cancer Institute (NCI)	Phase 1